Keywords

• Stivarga
• Regorafenib
• Stivarga raw material

Quick Details

• ProName: Stivarga/Regorafenib good quality
• CasNo: 1019206-88-2
• Molecular Formula:
• Appearance: white powder
• Application: in research
• DeliveryTime: within 3-5 days after receiving the pa...
• PackAge: Aluminum foil bag/ as requirements
• Port: China main port
• ProductionCapacity: 800 Kilogram/Month
• Purity: 99.00%
• Storage: Store in a cool dry place and keep awa...
• Transportation: by air or by sea
• LimitNum: 10 Gram

Superiority

       Inner Mongolia Yong Ming Technology Co.,Ltd--- a worthy to be depended and trusted Pharmaceutical Intermediates company. We make sure the good quality product and reasonable price. We have the good after-sales service, to solve any kinds of problems, the goal is making every customer satisfy with our company and gain the best reputation.

There are variety of products for your choose. Please contact with us at any time.

Our promise:

1. Good quality product and reasonable price~ make customers happy and save customers’ money

2. Delivery product on time~ save customers’ time

3. Professional packing~let the customers receive it successfully

4. Many payment instruments~convenient to pay 

5. Service customers forever~ to establish long-term cooperation relationship

Welcome to your inquire and suggestions, everyone here do the best for you!

Details

•  Product name:  Regorafenib hydrate

  CAS No.:  1019206-88-2

  Assay:  99%min

  Molecular Formula:  C21H17ClF4N4O4

  Molecular weight:  500.8306928

  Character:  White Crystal Powder

  MOQ:  10 grams

  Standard:  Enterprise Standard

  Packing:  foil bag or tin

  Delivery: Express courier

   

  Stivarga is a multiple kinase inhibitor that blocks several enzymes that promote tumor growth. The new Stivarga is safe and effective in the evaluation by a clinical trial of 199 patients with gastrointestinal stromal tumor in 199 patients, the gastrointestinal stromal tumor cannot be removed by surgery, and the use of Gleevec or SUTENT had progressive disease after treatment.

  In the trial, patients were randomly assigned to either Stivarga or placebo. At the same time, all patients received the best supportive treatment, including management of side effects and symptoms of cancer. In the trial, patients began to use either Stivarga or placebo when cancer progression or side effects were unacceptable. The results showed that the average length of cancer growth was 3.9 months longer in patients treated with Stivarga than in those treated with placebo. In the trial, patients who received placebos gained an opportunity to switch to Stivarga treatment after their cancer progressed.

   

  Stivarga the treatment of patients with advanced gastrointestinal stromal tumors (GIST). Stivarga is a multiple kinase inhibitor that blocks several enzymes that promote tumor growth.

Welcome to your inquire, thanks in  advance.

More information: mona@nmg-ym.com

Skype: live:mona_3363